SinoMab BioScience SMA 50
Was ist das SMA 50 von SinoMab BioScience?
SMA 50 von SinoMab BioScience Limited ist HKD$1 -20.50%
Was ist die Definition von SMA 50?
SMA 50 ist ein durchschnittlicher Aktienkurs der letzten 50 Tage, berechnet als ungewichteter Mittelwert der 50 letzten Schlusskurse.
Simple moving average of 50 days for a stock is an unweighted moving average over the past 50 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
SMA 50 von Unternehmen in Health Care Sektor auf HKSE im Vergleich zu SinoMab BioScience
Was macht SinoMab BioScience?
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Unternehmen mit sma 50 ähnlich SinoMab BioScience
- Element ASA hat SMA 50 von kr1 -0.13%
- MyFiziq hat SMA 50 von AUD$1 +93.20%
- Leverage Sha Etp 2071 hat SMA 50 von €1 -Inf%
- Polytec Asset hat SMA 50 von HKD$1 +0.00%
- Shanghai Dazhong Public Utilities () Co hat SMA 50 von HKD$1 -19.24%
- Beijing Urban Construction Design & Development Co hat SMA 50 von HKD$1 -4.40%
- SinoMab BioScience hat SMA 50 von HKD$1 -20.50%
- Arch Biopartners hat SMA 50 von CAD$1 +0.36%
- Asia Pacific Wire & Cable hat SMA 50 von $1 -4.30%
- ServiceSource International Inc hat SMA 50 von $1 +0.33%
- Blue Star Foods hat SMA 50 von $1 -90.95%
- B & D Strategic hat SMA 50 von HKD$1 -18.81%
- Unity Biotechnology Inc hat SMA 50 von $1 -7.01%